Jaguar Health, Inc.
JAGXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Cantor Fitzgerald | maintain | Overweight | Jul 7, 2021 |
| Aegis Capital | maintain | Buy | Nov 25, 2020 |
| H.C. Wainwright | maintain | Buy | Nov 25, 2020 |
| Ladenburg Thalmann | maintain | Buy | Nov 25, 2020 |
| Rodman & Renshaw | maintain | Buy | Nov 25, 2020 |
| H.C. Wainwright | maintain | Buy | Nov 18, 2019 |
| Ladenburg Thalmann | maintain | Buy | Sep 12, 2019 |
| Rodman & Renshaw | maintain | Buy | Jul 11, 2017 |
| Aegis Capital | maintain | Buy | Nov 12, 2015 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-444.29| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 19, 2026 | $-235.38 | $-565.81 | $1.2M | $4.2M |
| May 20, 2026 | $-2.04 | $-10.71 | $20.3M | $3.7M |
| Apr 7, 2026 | $-3.14 | $-1.49 | $3.2M | $4.2M |
| Nov 12, 2025 | $-2.20 | $-1.78 | $3.1M | $3.7M |
| Aug 14, 2025 | $-3.59 | $-2.50 | $3.0M | $3.3M |
| May 15, 2025 | $-5.84 | $-3.79 | $2.2M | $2.8M |
| Mar 31, 2025 | $-2.77 | $-2.77 | $3.5M | $3.1M |
| Nov 13, 2024 | $-9.19 | $-0.36 | $3.1M | $3.9M |
News
Mutation of the GUCY2C gene is the third IF-related congenital enteropathy, in addition to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), for which crofelemer has demonstrated benefit in reducing parenteral support needs in pediatric patients Company plans to file NDA for crofelemer for MVID in mid-2027 to obtain FDA approval SAN FRANCISCO, CA / ACCESS Newswire / October 21, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo…
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives Jaguar's rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for crofelemer for MVID in mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / October 14, 2026 / …
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for SBS-IF and microvillus inclusion disease (MVID) for crofelemer powder for oral solution, targeting a mid-2027 NDA filing for MVID SAN FRANCISCO, CA / ACCESS Newswire / October 14, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided a recap of the positive preliminary results presented on October 13, 2026 at the American College of G…
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives Jaguar's rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for crofelemer for MVID in mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / October 13, 2026 / …
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and short bowel syndrome (SBS) for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027 A recent Rareatives article shares the story of a young child living with MVID, highlighting the importance of family perspectives, supportive communication, and collaboration with clinicians in addressing rare intestinal diseases SAN FRAN…
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives SAN FRANCISCO, CA / ACCESS Newswire / October 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced that its Board of Directors has declared a special stock dividend (the "Special Stock Dividend") to holders of Jaguar Common Stock and certain outstanding warrants as of record on October 13, 2026. The Special Stock Dividend will consis…
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS-IF for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / September 29, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced the acceptance of an abstract on preliminary results of an ongoing open-label study of the company…
A rare-disease pipeline update and a thin post-split float are combining to send Jaguar Health (NASDAQ:JAGX) sharply higher. Jaguar Health stock is up 32% to $9.32 in morning trading, a surge rooted in company-specific forces.
Jaguar Health Inc. (NASDAQ:JAGX) shares are surging Friday morning, reversing Thursday's dilution-driven sell-off after the company announced additional debt-for-equity exchanges that reduced its outstanding debt by over $6.7 million and successfully retired a major promissory note.
Jaguar Health Inc. (NASDAQ:JAGX) shares are sliding Thursday afternoon as equity dilution concerns weigh on the micro-cap biopharmaceutical company following a debt-for-equity exchange.
Two biotech names are moving sharply lower Thursday morning while the sector benchmark grinds higher, a split move that puts the day's action on the companies themselves rather than on any broader rotation.
Two biotechnology names are lower in Wednesday morning trading for unrelated reasons, and the biotechnology sector itself isn't selling off. Jaguar Health (NASDAQ:JAGX) stock is at $14.
Jaguar Health Inc. (NASDAQ:JAGX) shares are plunging Wednesday morning as profit-taking reverses an explosive Tuesday rally sparked by regulatory fee waivers.
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / September 22, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the U.S. Food and Drug Administration (FDA) has granted Napo's request for a waiver of the fee a…
Reverse split approved at April 2026 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on September 17, 2026 SAN FRANCISCO, CA / ACCESS Newswire / September 15, 2026 / Jaguar Health, Inc. ( Nasdaq:JAGX ) ("Jaguar" or the "Company") today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio of 1-for-15, on Thursday, September 17, 2026 (the "E…
Shares of Jaguar Health Inc. (NASDAQ:JAGX) are trading lower Thursday morning as investors evaluate the clinical development timeline for the company's rare pediatric disease pipeline following an operational update.
Continuation of treatment with blinded doses of crofelemer in the extension phase of the trial will support company's plans to file an NDA in mid-2027 for MVID, an ultrarare pediatric disease SAN FRANCISCO, CA / ACCESS Newswire / September 10, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that all randomized pediatric MVID patients in Napo's pivotal crossover clinical trial have entered the single-blind extension phase to receive bli…
Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric and adult rare IF diseases, including microvillus inclusion disease (MVID) Company plans to file NDA for crofelemer for MVID in mid-2027 to obtain FDA approval SAN FRANCISCO, CA / ACCESS Newswire / September 4, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing…
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs Jaguar expects to make Neonorm Dog available through both Amazon and Chewy soon SAN FRANCISCO, CA / ACCESS Newswire / August 26, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced the initiation of the commercial launch of Neonorm Dog, a new extension of Jaguar…
Jaguar Health, Inc. (JAGX) Q2 2026 Earnings Call Prepared Remarks Transcript